Betaine for fatty liver disease with inflammation
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether a supplement called betaine can reduce liver fat and damage in people with a type of fatty liver disease that includes inflammation. Half of the participants will receive betaine, and half will receive a placebo (a pill with no active ingredient).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a body mass index (BMI) of 28 or higher.
- You have a diagnosis of fatty liver disease with at least one sign of metabolic syndrome (like high blood pressure, high blood sugar, or abnormal cholesterol).
- Your most recent liver enzyme test (ALT) was 50 or higher.
- You are not currently taking certain diabetes or weight-loss medications, or you have not taken them in the last 6 months.
- You are willing to make lifestyle changes (diet, exercise, and behavior) during the study.
- You are not pregnant or planning to become pregnant, and if you can become pregnant, you are using effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This study tests a new investigational drug called IMM-H014 for people with MASH, a type of fatty liver disease. The drug aims to reduce liver fat and improve liver health, and this trial will check its safety and effects.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.